PE66998A1 - Composiciones para el tratamiento con una dosis diaria para enfermedades producidas por la ciclooxigenasa-2 - Google Patents

Composiciones para el tratamiento con una dosis diaria para enfermedades producidas por la ciclooxigenasa-2

Info

Publication number
PE66998A1
PE66998A1 PE1997000379A PE00037997A PE66998A1 PE 66998 A1 PE66998 A1 PE 66998A1 PE 1997000379 A PE1997000379 A PE 1997000379A PE 00037997 A PE00037997 A PE 00037997A PE 66998 A1 PE66998 A1 PE 66998A1
Authority
PE
Peru
Prior art keywords
formulation
excipients
phenyl
cyclooxygenase
daily dose
Prior art date
Application number
PE1997000379A
Other languages
English (en)
Inventor
Bruno Hancock
Barry Gertz
Elliot Ehrich
Conrad Winters
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE66998(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Application filed by Merck & Co Inc, Merck Frosst Canada Inc filed Critical Merck & Co Inc
Publication of PE66998A1 publication Critical patent/PE66998A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CARACTERIZADAS PORQUE COMPRENDEN DE 5 mg A 125 mg DEL COMPUESTO 3-FENIL-4-(4-METILSULFONIL)FENIL)-2-(5H)-FURANONA; EN LA FORMULACION DE TABLETAS DE GRANULADO HUMEDO ADEMAS DE DICHO PRINCIPIO ACTIVO COMPRENDE: (A) CELULOSA MICROCRISTALINA, (B) MONOHIDRATO DE LACTOSA, (C) HIDROXIPROPILCELULOSA, (D) CROSCARMELOSA DE SODIO, (E) OXIDO DE HIERRO Y (F) ESTEARATO DE MAGNESIO; EN LA FORMULACION DE TABLETAS DE COMPRESION DIRECTA COMPRENDEN COMO EXCIPIENTES: (A), (D), (F) Y (G) ANHIDRATO DE LACTOSA; EN LA FORMULACION DE SUSPENSIONES ORALES COMPRENDEN COMO EXCIPIENTES: (H) SOLUCION DE SORBITOL, (I) POLIVINILPIRROLIDONA, (J) MONOLAURATO DE POLIOXIETILENO SORBITAN Y (K) ACIDO BENZOICO; EN LA FORMULACION DE UNA SOLUCION ORAL COMPRENDE COMO EXCIPIENTE: (L) OXIDO DE POLIETILENO 400. ESTAS COMPOSICIONES PRESENTAN POTENCIA, SEGURIDAD Y EFECTIVIDAD EN PEQUENAS DOSIS PARA INHIBIR LA CICLOXIGENASA-2, ADEMAS, PRESENTA UNA VIDA MEDIA PROLONGADA DE 15 HORAS O MAS, SIENDO UTILES EN EL TRATAMIENTO DE DOLENCIAS CRONICAS TALES COMO ARTRITIS O ENFERMEDAD DE ALZHEIMER, ENTRE OTROS
PE1997000379A 1996-05-17 1997-05-15 Composiciones para el tratamiento con una dosis diaria para enfermedades producidas por la ciclooxigenasa-2 PE66998A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Publications (1)

Publication Number Publication Date
PE66998A1 true PE66998A1 (es) 1998-10-24

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000379A PE66998A1 (es) 1996-05-17 1997-05-15 Composiciones para el tratamiento con una dosis diaria para enfermedades producidas por la ciclooxigenasa-2

Country Status (29)

Country Link
US (1) US6063811A (es)
EP (1) EP0910368A1 (es)
JP (1) JPH11512754A (es)
KR (1) KR100373622B1 (es)
CN (1) CN1140267C (es)
AR (1) AR012014A1 (es)
AU (1) AU3004997A (es)
BG (1) BG103000A (es)
BR (1) BR9709097A (es)
CA (1) CA2254061C (es)
CO (1) CO5050370A1 (es)
CZ (1) CZ291463B6 (es)
DZ (1) DZ2200A1 (es)
EA (1) EA001596B1 (es)
EE (1) EE03746B1 (es)
HK (1) HK1021623A1 (es)
HR (1) HRP970262A2 (es)
HU (1) HUP9902889A3 (es)
ID (1) ID16921A (es)
IL (1) IL126899A (es)
IS (1) IS4891A (es)
MY (1) MY116201A (es)
NO (1) NO985342L (es)
NZ (1) NZ332670A (es)
PE (1) PE66998A1 (es)
PL (1) PL188649B1 (es)
SK (1) SK284330B6 (es)
TR (1) TR199802345T2 (es)
WO (1) WO1997044028A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506024A (ja) * 1998-03-13 2002-02-26 メルク エンド カムパニー インコーポレーテッド 急性冠動脈虚血症候群および関連状態に対する併用療法および組成物
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
EP1239856A1 (en) * 1999-12-22 2002-09-18 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
CN100588395C (zh) 2000-06-13 2010-02-10 Wyeth公司 含有环氧化酶-2抑制剂的止痛和抗炎药物
ATE329583T1 (de) * 2000-08-18 2006-07-15 Pharmacia Corp Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
WO2002017896A2 (en) * 2000-08-29 2002-03-07 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US20040132780A1 (en) * 2001-05-04 2004-07-08 Allen Christopher P. Method and compositions for treating migraines
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition
IL160855A0 (en) * 2001-09-26 2004-08-31 Pharmacia Corp Intraorally disintegrating valdecoxib compositions
CN1602187A (zh) * 2001-10-10 2005-03-30 法马西亚公司 通过喷雾干燥法制备的口内崩解的伐地考昔组合物
KR20040089654A (ko) * 2002-03-07 2004-10-21 노파르티스 아게 약제학적 조성물
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ATE342722T1 (de) 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
CA2676413A1 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
MX2021005967A (es) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Formas purificadas de rofecoxib, métodos de fabricación y uso.
US20200323830A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
WO1995018799A1 (en) * 1994-01-10 1995-07-13 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors

Also Published As

Publication number Publication date
NZ332670A (en) 2000-07-28
EA199801017A1 (ru) 1999-04-29
IL126899A0 (en) 1999-09-22
WO1997044028A1 (en) 1997-11-27
PL329940A1 (en) 1999-04-26
CA2254061A1 (en) 1997-11-27
CA2254061C (en) 2003-12-02
JPH11512754A (ja) 1999-11-02
EP0910368A1 (en) 1999-04-28
SK284330B6 (sk) 2005-01-03
HUP9902889A2 (hu) 2002-01-28
DZ2200A1 (fr) 2004-06-20
CN1140267C (zh) 2004-03-03
HRP970262A2 (en) 1998-06-30
AR012014A1 (es) 2000-09-27
CO5050370A1 (es) 2001-06-27
HK1021623A1 (en) 2000-06-23
US6063811A (en) 2000-05-16
KR100373622B1 (ko) 2003-07-12
IL126899A (en) 2004-03-28
AU3004997A (en) 1997-12-09
EE03746B1 (et) 2002-06-17
EA001596B1 (ru) 2001-06-25
CZ373898A3 (cs) 1999-06-16
IS4891A (is) 1998-11-10
CN1225010A (zh) 1999-08-04
MY116201A (en) 2003-11-28
BR9709097A (pt) 1999-08-03
ID16921A (id) 1997-11-20
NO985342D0 (no) 1998-11-16
TR199802345T2 (xx) 1999-03-22
CZ291463B6 (cs) 2003-03-12
EE9800393A (et) 1999-06-15
NO985342L (no) 1998-11-16
PL188649B1 (pl) 2005-03-31
SK156798A3 (en) 2000-01-18
BG103000A (en) 1999-09-30
KR20000011082A (ko) 2000-02-25
HUP9902889A3 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
PE66998A1 (es) Composiciones para el tratamiento con una dosis diaria para enfermedades producidas por la ciclooxigenasa-2
CY1119001T1 (el) Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για ανευ νοηματος καταστολη και τη θεραπεια ασθενειας
TWI376364B (en) A pharmaceutical composition comprising an n, n-dihalogenated amino acid or a derivative thereof, and methods for use of the pharmaceutical composition
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
PE20030823A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
ES2159591T3 (es) Composicion de liberacion controlada.
PA8586501A1 (es) Tabletas dispersables que comprenden un derivado de acido benzoico
MX9300110A (es) Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
AR098997A2 (es) Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación
AR029542A1 (es) Composiciones para el cuidado bucal que contienen clorito y sus metodos
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
KR20070098947A (ko) 하이포할로우스 산과의 조합의 n-할로겐화 아미노산 및n,n-디할로겐화 아미노산
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
AR087210A2 (es) Formulacion farmaceutica de la sal sodica del telmisartan
CO5640072A2 (es) Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacion
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
AR038144A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
RU2006104009A (ru) Фармацевтическая препаративная форма
BR0210224A (pt) Formas de dosagem projetada para ser engolida diretamente e apresentada como uma formulação em comprimido ou cápsula deglutìvel, e, processo para preparação de uma forma de dosagem
AR025879A1 (es) Granulaciones de celulosa hidrolizada de sales de farmacos

Legal Events

Date Code Title Description
FC Refusal